Acknowledgement and Consent for Disclosure of

First Page		Document Content
Date: 2007-09-24 13:10:41 Immunosuppressants Macrolides Tetrazoles Zotarolimus Food and Drug Administration Medtronic Premarket approval Medicine Pharmaceutical sciences Pharmacology		Acknowledgement and Consent for Disclosure of Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 63,03 KB Share Document on Facebook

	Press release Embargo: May 28, 2015, 12:00 noon US Eastern Time A new tool to study an important anti-cancer and immunosuppressive target Structure explains why protein becomes insensitive to its inhibitor rapamycin DocID: 1gfmY - View Document
	WEDNESDAY, NOVEMBER 9, VOL. 15, NO. 215 TCT 2011 DocID: 19Zlb - View Document
	Review series Rapalogs and mTOR inhibitors as anti-aging therapeutics Dudley W. Lamming,1,2 Lan Ye,3 David M. Sabatini,1,2 and Joseph A. Baur3 1Whitehead Institute for Biomedical Research, Department of Biology, Howard DocID: 19zKo - View Document
	Microsoft Word - Mortality due to In-stent Thrombosis associated with Premature Termination of Dual Antiplatelet Therapy in Pat DocID: 10O3m - View Document
	Microsoft Word - Mortality due to In-stent Thrombosis associated with Premature Termination of Dual Antiplatelet Therapy in Pat DocID: TIEX - View Document